Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

The Lancet Gastroenterology and Hepatology

Volumn 4, Issue 1, 2019, Pages 45-51

  Asselah, Tarik ^a   Lee, Samuel S ^b   Yao, Betty B ^c   Nguyen, Tuan ^d   Wong, Florence ^e   Mahomed, Adam ^f   Lim, Seng Gee ^g   Abergel, Armand ^h   Sasadeusz, Joe ⁱ   Gane, Edward ^j   Zadeikis, Neddie ^c   Schnell, Gretja ^c   Zhang, Zhenzhen ^c   Porcalla, Ariel ^c   Mensa, Federico J ^c   Nguyen, Kinh ^k  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITY OF CALGARY   (Canada)

^c ABBVIE INC   (United States)

^d Research and Education Inc   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j Auckland Clinical Studies   (New Zealand)

^k NATIONAL HOSPITAL FOR TROPICAL DISEASES   (Viet Nam)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLECAPREVIR; INTERFERON; PIBRENTASVIR; RIBAVIRIN; SOFOSBUVIR; ABT-493; BENZIMIDAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CLINICAL OUTCOME; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; GOOD CLINICAL PRACTICE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; SCREENING; SUSTAINED VIROLOGIC RESPONSE; AGED; CHEMICALLY INDUCED; DRUG COMBINATION; GENETICS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BENZIMIDAZOLES; DRUG COMBINATIONS; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85057627268     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(18)30341-8     Document Type: Article

References (29)

1. Smith, DB, Bukh, J, Kuiken, C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
2. Messina, JP, Humphreys, I, Flaxman, A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
3. Asselah, T, Hassanein, T, Waked, I, Mansouri, A, Dusheiko, G, Gane, E, Eliminating hepatitis C within low-income countries—the need to cure genotypes 4, 5, 6. J Hepatol, 2017 published online Dec 8. DOI:10.1016/j.jhep.2017.11.037.
4. WHO. Combating hepatitis B and C to reach elimination by 2030. http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf?ua=1, 2016. (Accessed 10 August 2017)
5. Boyd, SD, Harrington, P, Komatsu, TE, et al. HCV genotype 4, 5 and 6: distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens. J Viral Hepat 25 (2018), 969–975.
6. Thong, VD, Akkarathamrongsin, S, Poovorawan, K, Tangkijvanich, P, Poovorawan, Y, Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 20 (2014), 2927–2940.
7. Li, C, Pham, VH, Abe, K, Lu, L, Nine additional complete genome sequences of HCV genotype 6 from Vietnam including new subtypes 6xb and 6xc. Virology 468–470 (2014), 172–177.
8. Li, C, Barnes, E, Newton, PN, et al. An expanded taxonomy of hepatitis C virus genotype 6: characterization of 22 new full-length viral genomes. Virology 476 (2015), 355–363.
9. Mavyret (glecaprevir/pibrentasvir). Prescribing information. 2017, AbbVie, Inc.
10. Ng, TI, Tripathi, R, Reisch, T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 62 (2018), e01620–e01717.
11. Ng, T, Krishnan, P, Pilot-Matias, T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 61 (2017), e02558–e02616.
12. Reau, N, Kwo, PY, Rhee, S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 68 (2018), 1298–1307.
13. Rockstroh, JK, Lacombe, K, Viani, RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 Study. Clin Infect Dis 67 (2018), 1010–1017.
14. Forns, X, Lee, SS, Valdes, J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17 (2017), 1062–1068.
15. Asselah, T, Kowdley, KV, Zadeikis, N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 16 (2018), 417–426.
16. Kwo, PY, Poordad, F, Asatryan, A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 67 (2017), 263–271.
17. Gane, E, Lawitz, E, Pugatch, D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377 (2017), 1448–1455.
18. Puoti, M, Foster, GR, Wang, S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol 69 (2018), 293–300.
19. Chao, DT, Abe, K, Nguyen, MH, Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 34 (2011), 286–296.
20. George, J, Burnevich, E, Sheen, IS, et al. Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepatol Commun 2 (2018), 595–606.
21. AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C virus. http://www.hcvguidelines.org, 2017. (Accessed 30 October 2017)
22. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69 (2018), 461–511.
23. Feld, JJ, Jacobson, IM, Hezode, C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
24. Abergel, A, Asselah, T, Metivier, S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 16 (2016), 459–464.
25. Gane, EJ, Hyland, RH, An, D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461.
26. Bourliere, M, Gordon, SC, Flamm, SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (2017), 2134–2146.
27. Jacobson, IM, Lawitz, E, Gane, EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 153 (2017), 113–122.
28. D'Ambrosio, R, Pasulo, L, Puoti, M, et al. Real-life effectiveness and safety of glecaprevir/pibrentasvir among 723 Italian patients with chronic hepatitis C: the Navigator-II study. J Hepatol, 68, 2018, S65.
29. Berg, T, Naumann, U, Stoehr, A, et al. First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: data from the German Hepatitis C-Registry. J Hepatol, 68, 2018, S37.